UPCC 20816: Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy (KEYNOTE-199)
99 years or below
All
Phase
2
1 Location
Brief description of study
Request for collaborative review: WIRB serving as IRB of record.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: TBD, tbd, tbd
-
Age: 99 years or below
-
Gender: All
Updated on
27 Aug 2018.
Study ID: 825773
